EP Vantage to Showcase New CAR-T Therapy Landscape Report at the 2016 BIO International Convention

Market intelligence group will also highlight first standardised consensus based European drug forecasts

LONDON & BOSTON & SAN FRANCISCO & TOKYO--()--EP Vantage, the editorial arm of life science market intelligence firm Evaluate Ltd., will highlight its latest report on the CAR-T therapy landscape at this year’s BIO International Convention, booth #7501 at the Moscone Center in San Francisco. Evaluate will also showcase its new data set for 2016 European drug sales, with forecasted earnings as far as 2022.

“The BIO conference is consistently one of the largest and most important events in the life sciences calendar,” said Lisa Urquhart, Editor at EP Vantage. “As CAR-T therapies move closer to the market the industry is really paying attention to see how they negotiate funding, clinical trials, manufacturing and regulatory approvals. We believe it’s an interesting and timely topic for BIO.”

The CAR-T therapy report will be the second from EP Vantage and Evaluate, as the company meets demand for up-to-date financial and life science analyses in this fast-growing field. As CAR-T therapies progress down the development pathway, the report explores some of the key challenges in their development and how they are being tackled, as the stage is set for what could be the first commercial US launch of anti-CD19 CAR-T products.

Evaluate will also highlight its new European drug forecasts, a unique data set for European market sizing, R&D horizon scanning and price comparison. It draws on real world government and company reported sales data with country level, consensus based product forecasts as far as 2022. Evaluate’s Head of Research, Anthony Raeside and Head of Forecasting, Antonio Iervolino will be in attendance at the BIO convention to discuss the new data sets, which also include historic drug sales, as well as volume and pricing for European products.

To download the complimentary CAR-T report, please visit here. For the European drug forecast media kit, please visit here.

About Evaluate Ltd.

Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2022. Our services include EvaluatePharmaEvaluateClinical Trials and EvaluateMedTech. Our award-winning editorial team, EP Vantage, leverages our strategic analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage.

Contacts

Evaluate and EP Vantage (for general questions)
Christine Lindgren, +1-617-866-3906
christine.lindgren@evaluategroup.com
or
Chempetitive Group (for U.S. media)
Trisha Rule, +1-858-230-4949
trule@chempetitive.com
or
Instinctif Partners (for non-U.S. media)
Gemma Howe, +44 (0) 20 7457 2020
evaluate@instinctif.com

Release Summary

EP Vantage, the editorial arm of Evaluate Ltd., will highlight its latest report on the CAR-T therapy landscape at this year’s BIO International Convention.

Contacts

Evaluate and EP Vantage (for general questions)
Christine Lindgren, +1-617-866-3906
christine.lindgren@evaluategroup.com
or
Chempetitive Group (for U.S. media)
Trisha Rule, +1-858-230-4949
trule@chempetitive.com
or
Instinctif Partners (for non-U.S. media)
Gemma Howe, +44 (0) 20 7457 2020
evaluate@instinctif.com